The TPD aims to preserve a high level of European public health and support the functioning of the internal market of tobacco products in the EU

Provide regulation of
— tobacco products
— novel tobacco products
— electronic cigarette products

The JATC is a collaborative action between the European Commission and the EU Member States built on evidence-based tobacco control policies with the overarching aim to be implemented at a national, regional and European level in order to improve Public Health protection in the EU.

Support the implementation of the Tobacco Products Directive throughout the 28 EU MS
SPECIFIC AIMS OF THE PROJECT

- Support the dissemination of information to the target groups
- Enhance the ease of access to the data collected, through the EU Common Entry Gate
- Monitor and provide support to the tasks of tobacco and e-cigarette products regulations
- Assist EU MS networking and enhance collaborations between laboratories for tobacco evaluation
- Support EU MS in the process of monitoring and updating priority additives
- Integrate the JATC results into national policies

TARGET GROUPS

- EU Regulators and national policymakers
- International and National Tobacco control stakeholders
- Researchers
- General public
**ORGANIZATIONAL STRUCTURE**

- **COORDINATION TEAM**
- **STEERING COMMITTEE**
- **CONSORTIUM MEETING**

**HELENNIC CANCER SOCIETY**

**WORK PACKAGE LEADERS**

**ALL PARTNERS**

**COORDINATION TEAM**

- **Project Coordinator**: Prof. Panagiotis Behrakis
- **Project Associate Coordinators**: Dr. Constantine Vardavas, Dr. Anna Tzortzi
- **Project Manager**: Dimitris Kagkos
- **Project Secretariat**: Penelope Stambouli

**PROJECT MANAGEMENT STRUCTURE**

- **EUROPEAN COMMISSION**
- **ADVISORY BOARD**

**WP 1**

**STEERING COMMITTEE**

**WP 5**

**WP 6** | **WP 7** | **WP 8** | **WP 9**

**WP 2**

**WP 4**

**WP 3**
PARTICIPANTS
31 PROJECT PARTNERS/INSTITUTIONS

1 | HCS
Hellenic Cancer Society, Greece
2 | AGES
Austrian Agency for Health and Food Safety, Austria
3 | BHTC
Federal Public Service Health, Belgium
4 | NCPHA
National Center of Public Health and Analyses, Bulgaria
5 | MoH-CY
Ministry of Health, Cyprus
6 | SIK
Danish Safety Technology Authority
7 | TA
Estonian Health Board
8 | ANSES
French agency for food, environmental and occupational health & safety
9 | BfR
Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung), Germany
10 | APTL-CERTH
Aerosol & Particle Technology Laboratory, Chemical Process & Energy Resources Institute, Centre for Research & Technology, Greece
11 | SU-(SE)
Semmelweis University, Hungary
12 | DOHI
Directorate of Health, Iceland
13 | HSE
Health Service Executive, Ireland
14 | IRCCS-IRFMN
Istituto di Ricerche Farmacologiche “Mario Negri”, Italy
15 | ISS
National Institute of Health Istituto Superiore di Sanita, Italy
16 | MOH-IT
Ministry of Health, Italy
17 | HI
Health Inspectorate, Ministry of Health, Latvia
18 | NTAKD
Drug, tobacco and alcohol control department, Lithuania
19 | **NVSPL**  
National Public Health Surveillance Laboratory, Lithuania

20 | **DEH**  
Environmental Health Directorate, Malta

21 | **RIVM**  
National Institute for Public Health and the Environment, The Netherlands

22 | **NIPH**  
Institute of Public Health, Norway

23 | **NOMA**  
Norwegian Medicines Agency

24 | **MS-DGS**  
Directorate General of Health, Portugal

25 | **BATUT-IPHS**  
Institute of Public Health, Serbia

26 | **MZLOH**  
National Laboratory of Health, Environment and Food, Slovenia

27 | **ICO**  
Catalan Institute of Oncology, Spain – included affiliated partner **IDIBELL**

28 | **CSJA**  
Consejería de Salud Junta de Andalucía, Spain – including affiliated partners **AGAPA** and **FPS**

29 | **FOHM**  
The Public Health Agency, Sweden

30 | **UK-DH**  
Department of Health, UK

31 | **HTC**  
Hellenic Thoracic Society, Greece

---

**W/P LEADERS**

1 | **HCS**  
Hellenic Cancer Society, Greece

2 | **AGES**  
Austrian Agency for Health and Food Safety, Austria

5 | **MoH CY**  
Ministry of Health, Cyprus

6 | **SIK**  
Danish Safety Technology Authority

14 | **IRCCS-IRFMN**  
Istituto di Ricerche Farmacologiche “Mario Negri”, Italy

21 | **RIVM**  
National Institute for Public Health and the Environment, The Netherlands

25 | **BATUT-IPHS**  
Institute of Public Health, Serbia

27 | **ICO**  
Catalan Institute of Oncology, Spain – included affiliated partner **IDIBELL**
<table>
<thead>
<tr>
<th>INSTITUTION</th>
<th>COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO - FCTC</td>
<td>Switzerland</td>
</tr>
<tr>
<td>European Respiratory Society (ERS)</td>
<td>Switzerland</td>
</tr>
<tr>
<td>CHEST</td>
<td>USA</td>
</tr>
<tr>
<td>Institute of Public Health-ACG</td>
<td>Greece</td>
</tr>
<tr>
<td>Aer Pur Romania</td>
<td>Romania</td>
</tr>
<tr>
<td>National Supervisory Authority for Welfare and Health (Valvira)</td>
<td>Finland</td>
</tr>
<tr>
<td>Bureau for Chemical Substances</td>
<td>Poland</td>
</tr>
<tr>
<td>Norwegian Directorate of Health</td>
<td>Norway</td>
</tr>
<tr>
<td>National Center for Public Health</td>
<td>Moldova</td>
</tr>
<tr>
<td>Universitat Internacional de Catalunya (UIC-Barcelona)</td>
<td>Spain</td>
</tr>
<tr>
<td>Individual Expert</td>
<td>Hungary</td>
</tr>
<tr>
<td>Lithuanian University of Health Sciences</td>
<td>Lithuania</td>
</tr>
<tr>
<td>Athens Medical Center</td>
<td>Greece</td>
</tr>
</tbody>
</table>
WORK PACKAGES 1-9

01 Coordination
Hellenic Cancer Society

02 Dissemination
HCS, MoHCY, SE

03 Evaluation
HCS

04 Integration into National Policies & Sustainability
HCS, NCPHA, MoHCY, TA, ANSES, BfR, SE, HSE, IRFMN, NTAKD, CSJA

05 Common Entry Gate (CEG) data extraction and handling
HCS, AGES, BHTC, NCPA, SIK, TA, ANSES, MOHIT, NTAKD, NOMA, MS, NLZOH, CSJA, FOHM, UK-DOH

06 Tobbaco Product Evaluation
HCS, AGES, BHTC, SIK, ANSES, BfR, CERTH, HTS, HSE, IRFMN, ISS, MOHIT, NTAKD, RIVM, NIPH, MS, NLZOH, ICO, CSJA, FOHM, UK-DOH

07 E-Cigarette Product Evaluation
HCS, AGES, BHTC, ANSES, BfR, CERTH, HTS, DOHI, HSE, IRFMN, ISS, MOH-IT, HI, NTAKD, RIVM, NIPH, NOMA, MS, ICO, CSJA, FOHM, UK-DOH

08 Laboratory Verification, Collaboration & Analyses
HCS, AGES, BfR, CERTH, HTS, IRFMN, NVSPL, RIVM, NLZOH, CSJA

09 Additives Subject to Enhanced Reporting Obligations
HCS, SIK, ANSES, BfR, IRFMN, ISS, RIVM, NIPH, CSJA, FOHM
EXPECTED OUTCOMES

- Increased EU MS implementation of the TPD through the provision of support and technical/scientific capacity to EU regulators
- Increased EU MS regulator training through the provision of capacity building (toolkits, e-learning)
- Common approach on handling tobacco products evidence based decisions across EU MS, within the context of their national legislative approach
- Increased data sharing and collaborations between EU MS on tobacco product regulatory science
- Responses to questions on “burning topics” as brought forward by EU MS regulators
- Increased literacy on tobacco products design, constituents and toxicity by regulators and the public
- Close monitoring of e-cigarette compliance to the TPD across the EU MS
- Increased knowledge of e-cigarette design parameters, ingredients and emissions
- Enhanced collaborations between EU MS laboratories for tobacco products ingredients and emissions measurements
- Increased scientific scrutiny and decisions on potential priority additives within tobacco products
- Greater access to data on tobacco products and e-cigarettes, in order to fuel general population awareness and enhance research and policy actions. The provision of such public data will be an unprecedented opportunity for tobacco control research.
“This activity is part of the project / joint action ‘761297 / JATC’ which has received funding from the European Union’s Health Programme (2014-2020).”